甲状腺功能亢进患者骨密度与骨代谢生化指标的改变

目的研究甲状腺功能亢进（甲亢）患者骨密度与骨代谢生化指标的改变，探讨甲亢患者骨质疏松发生的机制。方法应用双能X线测定仪（DEXA）检测124例甲亢患者骨密（BMD），同时测定血清FT3、FT4、TSH，碱性磷酸酶（ALP）、骨钙素（BGP）、尿脱氧吡啶啉（D-pyd）、尿羟脯氨酸（HOP），并以60例健康者作为对照组。结果甲亢患者并发骨质疏松发生率21．8％，并发骨量减少占37．1蹦，与对照组比较，甲亢患者骨密度明显低于对照姐（P〈0．01），各骨代谢指标明显升高（P〈0．01）。结论甲亢时各骨代谢指标均明显升高，但以破骨指标升高为主，呈高转换型骨质疏松。在治疗甲亢的同时，应积极防治骨质疏松。

TRANSFER ON BONE MINERAL DENSITY AND BONE METABOLISM BIOCHEMICAL MARKER IN HYPERTHYROIDISM

Objective To study the transfer on bone mineral density and bone metabolic biochemical marker in hyperthyroidism, and discuss the mechanism of osteoporosis in hyperthyroidism. Methods Bone mineral density was observed using dual-energy X-ray absorption metry in 124 cases with hyperthyroidism and 60 normal controls, in addition, their serum FT3, FT4, TSH, alkaline phosphatase (ALP), ostecocalcin (BGP), urina deoxy pydidioline (D-pyd) and hydroxyproline(HOP) level were measured as well. Results Osteoporosis rate was 21.8% and osteopenia rate was 37.1% in hyperthyroidism patients. Compared with control group, bone mineral density in patients with hyperthyroidism was significantly decreased (P<0.01), and values of bone metabolic biochemical markers were significantly increased (P<0.01). Conclusion Values of bone metabolic biochemical markers in hyperthyroidism are significantly increased, especially those of osteoclasts, which displays high turnover osteoporosis. Therefore, it is important to prevent and treat osteoporosis while treating hyperthyroidism.